A share price of Denali Therapeutics Inc [DNLI] is currently trading at $17.95, up 5.09%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DNLI shares have gain 12.05% over the last week, with a monthly amount glided 2.16%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Cantor Fitzgerald upgraded its rating to Overweight on April 10, 2025. Deutsche Bank started tracking the stock assigning a Buy rating and suggested a price target of $31 on February 11, 2025. Robert W. Baird initiated its recommendation with an Outperform and recommended $31 as its price target on January 07, 2025. In a note dated December 16, 2024, Stifel upgraded a Buy rating on this stock but restated the target price of $37.
Denali Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $10.57 and $24.34. Currently, Wall Street analysts expect the stock to reach $33 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $17.95 at the most recent close of the market. An investor can expect a potential return of 83.84% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.46 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Denali Therapeutics Inc [NASDAQ:DNLI] is 9.79. Also, the Quick Ratio is 9.79, while the Cash Ratio stands at 1.01.
Transactions by insiders
Recent insider trading involved Watts Ryan J., President and CEO, that happened on Jan 06 ’26 when 35198.0 shares were sold. COFO and Secretary, Schuth Alexander O. completed a deal on Jan 06 ’26 to sell 17218.0 shares. Meanwhile, Consultant Ho Carole bought 17218.0 shares on Jan 06 ’26.
